TISCY vs SMMT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TISCY · TAISEI CORP UNSP ADR EACH REP 0.25 ORD SHS$16.74 ▼ 3.18%
SMMT · Summit Therapeutics$16.33 ▲ 15.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TISCY -5.1%
- SMMT -10.8%
Head to head
| Metric | TISCY | SMMT |
|---|---|---|
| Price | $16.74 | $16.33 |
| Change today | ▼ 3.18% | ▲ 15.08% |
| Market cap | $13.05B | $13.06B |
| Return, 3 months | -18.8% | +9.8% |
| Return, year to date | -26.3% | -6.6% |
| Return, 1 year | -5.1% | -10.2% |
| P/E (TTM) | 10.1 | – |
| P/B | 1.8 | 23.1 |
| P/E percentile vs own 5y | – | 26th |
| Dividend yield | 2.90% | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | +61.9% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | -192.5% |
| Analyst target vs. price | – | +81.8% |
| Analyst buy share | – | 62% |
| RSI (14) | 44 | 53 |
| 30-day volatility | 107.0% | 86.2% |
| Max drawdown, 1 year | -51.2% | -52.9% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SMMT is the largest of the group by market value.
- TISCY has returned the most over the past year.
- SMMT has been the calmest stock over the last 30 days.